Request for Covid-19 Impact Assessment of this Report

Healthcare

United States Biologic Drugs Market Report 2017

  • QYR1554709
  • 99 Pages
  • September 2017
  • Healthcare
Download Sample    Get Discount   
 
In this report, the United States Biologic Drugs market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

The West

Southwest

The Middle Atlantic

New England

The South

The Midwest

with sales (volume), revenue (value), market share and growth rate of Biologic Drugs in these regions, from 2012 to 2022 (forecast).

United States Biologic Drugs market competition by top manufacturers/players, with Biologic Drugs sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

Roche

Abbott Laboratories

Johnson & Johnson

Merck & Co.

Pfizer

Amgen

Sanofi

Novartis

Eli Lilly

Amgen

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

Humira

Remicade

Rituxan

Enbrel

Lantus

Avastin

Herceptin

Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Biologic Drugs for each application, including

Diabetes

Inflammation

Auto-Immune Diseases

Blood Diseases

Cardiovascular Diseases

Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Table of Contents

United States Biologic Drugs Market Report 2017

1 Biologic Drugs Overview

1.1 Product Overview and Scope of Biologic Drugs

1.2 Classification of Biologic Drugs by Product Category

1.2.1 United States Biologic Drugs Market Size (Sales Volume) Comparison by Type (2012-2022)

1.2.2 United States Biologic Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2016

1.2.3 Humira

1.2.4 Remicade

1.2.5 Rituxan

1.2.6 Enbrel

1.2.7 Lantus

1.2.8 Avastin

1.2.9 Herceptin

1.2.10 Others

1.3 United States Biologic Drugs Market by Application/End Users

1.3.1 United States Biologic Drugs Market Size (Consumption) and Market Share Comparison by Application (2012-2022)

1.3.2 Diabetes

1.3.3 Inflammation

1.3.4 Auto-Immune Diseases

1.3.5 Blood Diseases

1.3.6 Cardiovascular Diseases

1.3.7 Others

1.4 United States Biologic Drugs Market by Region

1.4.1 United States Biologic Drugs Market Size (Value) Comparison by Region (2012-2022)

1.4.2 The West Biologic Drugs Status and Prospect (2012-2022)

1.4.3 Southwest Biologic Drugs Status and Prospect (2012-2022)

1.4.4 The Middle Atlantic Biologic Drugs Status and Prospect (2012-2022)

1.4.5 New England Biologic Drugs Status and Prospect (2012-2022)

1.4.6 The South Biologic Drugs Status and Prospect (2012-2022)

1.4.7 The Midwest Biologic Drugs Status and Prospect (2012-2022)

1.5 United States Market Size (Value and Volume) of Biologic Drugs (2012-2022)

1.5.1 United States Biologic Drugs Sales and Growth Rate (2012-2022)

1.5.2 United States Biologic Drugs Revenue and Growth Rate (2012-2022)

2 United States Biologic Drugs Market Competition by Players/Suppliers

2.1 United States Biologic Drugs Sales and Market Share of Key Players/Suppliers (2012-2017)

2.2 United States Biologic Drugs Revenue and Share by Players/Suppliers (2012-2017)

2.3 United States Biologic Drugs Average Price by Players/Suppliers (2012-2017)

2.4 United States Biologic Drugs Market Competitive Situation and Trends

2.4.1 United States Biologic Drugs Market Concentration Rate

2.4.2 United States Biologic Drugs Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Biologic Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Biologic Drugs Sales (Volume) and Revenue (Value) by Region (2012-2017)

3.1 United States Biologic Drugs Sales and Market Share by Region (2012-2017)

3.2 United States Biologic Drugs Revenue and Market Share by Region (2012-2017)

3.3 United States Biologic Drugs Price by Region (2012-2017)

4 United States Biologic Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)

4.1 United States Biologic Drugs Sales and Market Share by Type (Product Category) (2012-2017)

4.2 United States Biologic Drugs Revenue and Market Share by Type (2012-2017)

4.3 United States Biologic Drugs Price by Type (2012-2017)

4.4 United States Biologic Drugs Sales Growth Rate by Type (2012-2017)

5 United States Biologic Drugs Sales (Volume) by Application (2012-2017)

5.1 United States Biologic Drugs Sales and Market Share by Application (2012-2017)

5.2 United States Biologic Drugs Sales Growth Rate by Application (2012-2017)

5.3 Market Drivers and Opportunities

6 United States Biologic Drugs Players/Suppliers Profiles and Sales Data

6.1 Roche

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Biologic Drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Roche Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.1.4 Main Business/Business Overview

6.2 Abbott Laboratories

6.2.2 Biologic Drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Abbott Laboratories Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.2.4 Main Business/Business Overview

6.3 Johnson & Johnson

6.3.2 Biologic Drugs Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Johnson & Johnson Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.3.4 Main Business/Business Overview

6.4 Merck & Co.

6.4.2 Biologic Drugs Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Merck & Co. Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.4.4 Main Business/Business Overview

6.5 Pfizer

6.5.2 Biologic Drugs Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Pfizer Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.5.4 Main Business/Business Overview

6.6 Amgen

6.6.2 Biologic Drugs Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Amgen Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.6.4 Main Business/Business Overview

6.7 Sanofi

6.7.2 Biologic Drugs Product Category, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Sanofi Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.7.4 Main Business/Business Overview

6.8 Novartis

6.8.2 Biologic Drugs Product Category, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Novartis Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.8.4 Main Business/Business Overview

6.9 Eli Lilly

6.9.2 Biologic Drugs Product Category, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 Eli Lilly Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.9.4 Main Business/Business Overview

6.10 Amgen

6.10.2 Biologic Drugs Product Category, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Amgen Biologic Drugs Sales, Revenue, Price and Gross Margin (2012-2017)

6.10.4 Main Business/Business Overview

7 Biologic Drugs Manufacturing Cost Analysis

7.1 Biologic Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Biologic Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Biologic Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Biologic Drugs Major Manufacturers in 2016

8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 United States Biologic Drugs Market Size (Value and Volume) Forecast (2017-2022)

11.1 United States Biologic Drugs Sales Volume, Revenue Forecast (2017-2022)

11.2 United States Biologic Drugs Sales Volume Forecast by Type (2017-2022)

11.3 United States Biologic Drugs Sales Volume Forecast by Application (2017-2022)

11.4 United States Biologic Drugs Sales Volume Forecast by Region (2017-2022)

12 Research Findings and Conclusion

13 Appendix

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

List of Tables and Figures

Figure Product Picture of Biologic Drugs

Figure United States Biologic Drugs Market Size (K Units) by Type (2012-2022)

Figure United States Biologic Drugs Sales Volume Market Share by Type (Product Category) in 2016

Figure Humira Product Picture

Figure Remicade Product Picture

Figure Rituxan Product Picture

Figure Enbrel Product Picture

Figure Lantus Product Picture

Figure Avastin Product Picture

Figure Herceptin Product Picture

Figure Others Product Picture

Figure United States Biologic Drugs Market Size (K Units) by Application (2012-2022)

Figure United States Sales Market Share of Biologic Drugs by Application in 2016

Figure Diabetes Examples

Table Key Downstream Customer in Diabetes

Figure Inflammation Examples

Table Key Downstream Customer in Inflammation

Figure Auto-Immune Diseases Examples

Table Key Downstream Customer in Auto-Immune Diseases

Figure Blood Diseases Examples

Table Key Downstream Customer in Blood Diseases

Figure Cardiovascular Diseases Examples

Table Key Downstream Customer in Cardiovascular Diseases

Figure Others Examples

Table Key Downstream Customer in Others

Figure United States Biologic Drugs Market Size (Million USD) by Region (2012-2022)

Figure The West Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure Southwest Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Middle Atlantic Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure New England Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The South of US Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure The Midwest Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Biologic Drugs Sales (K Units) and Growth Rate (2012-2022)

Figure United States Biologic Drugs Revenue (Million USD) and Growth Rate (2012-2022)

Figure United States Biologic Drugs Market Major Players Product Sales Volume (K Units) (2012-2017)

Table United States Biologic Drugs Sales (K Units) of Key Players/Suppliers (2012-2017)

Table United States Biologic Drugs Sales Share by Players/Suppliers (2012-2017)

Figure 2016 United States Biologic Drugs Sales Share by Players/Suppliers

Figure 2017 United States Biologic Drugs Sales Share by Players/Suppliers

Figure United States Biologic Drugs Market Major Players Product Revenue (Million USD) (2012-2017)

Table United States Biologic Drugs Revenue (Million USD) by Players/Suppliers (2012-2017)

Table United States Biologic Drugs Revenue Share by Players/Suppliers (2012-2017)

Figure 2016 United States Biologic Drugs Revenue Share by Players/Suppliers

Figure 2017 United States Biologic Drugs Revenue Share by Players/Suppliers

Table United States Market Biologic Drugs Average Price (USD/Unit) of Key Players/Suppliers (2012-2017)

Figure United States Market Biologic Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2016

Figure United States Biologic Drugs Market Share of Top 3 Players/Suppliers

Figure United States Biologic Drugs Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Biologic Drugs Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Biologic Drugs Product Category

Table United States Biologic Drugs Sales (K Units) by Region (2012-2017)

Table United States Biologic Drugs Sales Share by Region (2012-2017)

Figure United States Biologic Drugs Sales Share by Region (2012-2017)

Figure United States Biologic Drugs Sales Market Share by Region in 2016

Table United States Biologic Drugs Revenue (Million USD) and Market Share by Region (2012-2017)

Table United States Biologic Drugs Revenue Share by Region (2012-2017)

Figure United States Biologic Drugs Revenue Market Share by Region (2012-2017)

Figure United States Biologic Drugs Revenue Market Share by Region in 2016

Table United States Biologic Drugs Price (USD/Unit) by Region (2012-2017)

Table United States Biologic Drugs Sales (K Units) by Type (2012-2017)

Table United States Biologic Drugs Sales Share by Type (2012-2017)

Figure United States Biologic Drugs Sales Share by Type (2012-2017)

Figure United States Biologic Drugs Sales Market Share by Type in 2016

Table United States Biologic Drugs Revenue (Million USD) and Market Share by Type (2012-2017)

Table United States Biologic Drugs Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Biologic Drugs by Type (2012-2017)

Figure Revenue Market Share of Biologic Drugs by Type in 2016

Table United States Biologic Drugs Price (USD/Unit) by Types (2012-2017)

Figure United States Biologic Drugs Sales Growth Rate by Type (2012-2017)

Table United States Biologic Drugs Sales (K Units) by Application (2012-2017)

Table United States Biologic Drugs Sales Market Share by Application (2012-2017)

Figure United States Biologic Drugs Sales Market Share by Application (2012-2017)

Figure United States Biologic Drugs Sales Market Share by Application in 2016

Table United States Biologic Drugs Sales Growth Rate by Application (2012-2017)

Figure United States Biologic Drugs Sales Growth Rate by Application (2012-2017)

Table Roche Basic Information List

Table Roche Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Roche Biologic Drugs Sales Growth Rate (2012-2017)

Figure Roche Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Roche Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Abbott Laboratories Basic Information List

Table Abbott Laboratories Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Abbott Laboratories Biologic Drugs Sales Growth Rate (2012-2017)

Figure Abbott Laboratories Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Abbott Laboratories Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Johnson & Johnson Basic Information List

Table Johnson & Johnson Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Johnson & Johnson Biologic Drugs Sales Growth Rate (2012-2017)

Figure Johnson & Johnson Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Johnson & Johnson Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Merck & Co. Basic Information List

Table Merck & Co. Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Merck & Co. Biologic Drugs Sales Growth Rate (2012-2017)

Figure Merck & Co. Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Merck & Co. Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Pfizer Basic Information List

Table Pfizer Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Pfizer Biologic Drugs Sales Growth Rate (2012-2017)

Figure Pfizer Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Pfizer Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Amgen Basic Information List

Table Amgen Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Amgen Biologic Drugs Sales Growth Rate (2012-2017)

Figure Amgen Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Amgen Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Sanofi Basic Information List

Table Sanofi Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Sanofi Biologic Drugs Sales Growth Rate (2012-2017)

Figure Sanofi Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Sanofi Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Novartis Basic Information List

Table Novartis Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Novartis Biologic Drugs Sales Growth Rate (2012-2017)

Figure Novartis Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Novartis Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Eli Lilly Basic Information List

Table Eli Lilly Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Eli Lilly Biologic Drugs Sales Growth Rate (2012-2017)

Figure Eli Lilly Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Eli Lilly Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Amgen Basic Information List

Table Amgen Biologic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Amgen Biologic Drugs Sales Growth Rate (2012-2017)

Figure Amgen Biologic Drugs Sales Market Share in United States (2012-2017)

Figure Amgen Biologic Drugs Revenue Market Share in United States (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Biologic Drugs

Figure Manufacturing Process Analysis of Biologic Drugs

Figure Biologic Drugs Industrial Chain Analysis

Table Raw Materials Sources of Biologic Drugs Major Players/Suppliers in 2016

Table Major Buyers of Biologic Drugs

Table Distributors/Traders List

Figure United States Biologic Drugs Sales Volume (K Units) and Growth Rate Forecast (2017-2022)

Figure United States Biologic Drugs Revenue (Million USD) and Growth Rate Forecast (2017-2022)

Figure United States Biologic Drugs Price (USD/Unit) Trend Forecast (2017-2022)

Table United States Biologic Drugs Sales Volume (K Units) Forecast by Type (2017-2022)

Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Type (2017-2022)

Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Type in 2022

Table United States Biologic Drugs Sales Volume (K Units) Forecast by Application (2017-2022)

Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Application (2017-2022)

Figure United States Biologic Drugs Sales Volume (K Units) Forecast by Application in 2022

Table United States Biologic Drugs Sales Volume (K Units) Forecast by Region (2017-2022)

Table United States Biologic Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Biologic Drugs Sales Volume Share Forecast by Region (2017-2022)

Figure United States Biologic Drugs Sales Volume Share Forecast by Region in 2022

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

 
Purchase Options

* Taxes/Fees, If applicable will be
added during checkout. All prices in USD.

Need More Information

Contact Us

+ 1-888-961-4454

Drop Us an email at

help@bigmarketresearch.com

Similar Reports

Regenerative Medicine Market by Product Type (Cell Therapy, Gene Therapy, Tissue Engineering, and Small Molecule & Biologic), Material (Synthetic Material, Biologically Derived Material, Genetically Engineered Material, and Pharmaceutical), and Application (Cardiovascular, Oncology, Dermatology, Musculoskeletal, Wound Healing, Ophthalmology, Neurology, and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023

The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...

  • Publish Date: May 29, 2018
  • $5370
World Medical Robotics and Computer - Assisted Surgery Market - Opportunities and Forecasts, 2015 - 2022

The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...

  • Publish Date: May 1, 2016
  • $5370